Kristi Sutton, MD
Internal Medicine · Bryant, ARNPI 1720202989
Payments from drug & device makers
Across 96 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$175
- Novo Nordisk$154
- AbbVie$129
- Otsuka America Pharmaceutical, Inc.$125
- Amgen$120
- Abbott$113
- plus $832 from 17 others
What the payments were for
- Food & beverage$1,59797%
- Education$503%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 10 | $175 |
| Novo Nordisk | 10 | $154 |
| AbbVie(2 entities) | 9 | $129 |
| Otsuka America Pharmaceutical, Inc. | 5 | $125 |
| Amgen | 6 | $120 |
| Abbott | 6 | $113 |
| Currax Pharmaceuticals LLC | 6 | $107 |
| Astellas Pharma US Inc | 5 | $94 |
| Sumitomo Pharma America, Inc. | 6 | $92 |
| GSK | 5 | $80 |
| Lilly USA, LLC | 5 | $69 |
| Lundbeck LLC | 4 | $63 |
| Sunovion Pharmaceuticals Inc. | 4 | $60 |
| AstraZeneca | 3 | $56 |
| Johnson & Johnson | 3 | $47 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Eisai Inc. | 1 | $34 |
| Merck | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Corium, LLC | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$1,647 in reported general payments places this provider in the 75th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 136 | $190,575 |
| EliquisApixaban | 189 | $174,550 |
| XareltoRivaroxaban | 60 | $71,468 |
| MounjaroTirzepatide | 34 | $49,933 |
| FarxigaDapagliflozin Propanediol | 22 | $24,254 |
| MyrbetriqMirabegron | 22 | $22,310 |
| JanuviaSitagliptin Phosphate | 15 | $21,320 |
| JardianceEmpagliflozin | 15 | $21,230 |
| CreonLipase/Protease/Amylase | 13 | $19,104 |
| GemtesaVibegron | 23 | $12,779 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $9,980 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $7,873 |
| Pravastatin Sodium | 637 | $7,442 |
| Levothyroxine Sodium | 890 | $7,150 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $6,925 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $154 | $190,575136 claims |
| PfizerEliquis, Premarin | $175 | $181,330205 claims |
| Johnson & JohnsonXarelto | $47 | $71,46860 claims |
| Lilly USA, LLCMounjaro | $69 | $49,93334 claims |
| AstraZenecaFarxiga | $56 | $24,25422 claims |
| AbbVieCreon, Synthroid | $129 | $23,259123 claims |
| Astellas Pharma US IncMyrbetriq | $94 | $22,31022 claims |
| MerckJanuvia | $19 | $21,32015 claims |
| Boehringer IngelheimJardiance | $14 | $21,23015 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $92 | $12,77923 claims |
| GSKTrelegy Ellipta | $80 | $6,92511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Bryant
- Christopher SkelleyBryant$9K
- Tyler NelsonBryant$9K
- Priyantha WijewardaneLittle Rock$43.6M
- Joseph RoseLittle Rock$1.1M
- David JohnsonSearcy$630K
- Kathleen GannonRogers$450K
- Alexander KaczenskiLittle Rock$305K
- John HendersonSearcy$102K
- David PyleJonesboro$93K
- Manisha SinghLittle Rock$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.